TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34566853

Group type: EXPERIMENTAL
Intervention: Early Supported Discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 34567118

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Tumor size
Number of subjects: 918
Study: 34567926

Group type: EXPERIMENTAL
Intervention: ipragliflozin
Number of subjects: 11051
Study: 34568006

Group type: EXPERIMENTAL
Intervention: 2173 CAR T cells
Number of subjects: 0
Study: 34568057

Group type: EXPERIMENTAL
Intervention: Robotic-assisted thoracoscopic surgery (RATS)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 83
Study: 34568058

Group type: EXPERIMENTAL
Intervention: Dasatinib and Osimertinib
Number of subjects: 10
Study: 34568066

Group type: EXPERIMENTAL
Intervention: Treosulfan-based conditioning regimen (42 g/m²)
Number of subjects: 0
Study: 34568241

Group type: EXPERIMENTAL
Intervention: Prolonged Slow Expiration Technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34568375

Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 34568387

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 0
Study: 34568719

Group type: EXPERIMENTAL
Intervention: Integrated 31-GEP neural network algorithm incorporating clinicopathologic features with the continuous 31-GEP score.
Number of subjects: 3372
Study: 34568984

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE severity item
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE interference item
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE severity and interference items
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE severity and interference response categories
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE items
Number of subjects: 142
Study: 34569250

Group type: EXPERIMENTAL
Intervention: Plaque erosion treatment with stenting
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Age group comparison
Number of subjects: 579
Study: 34569278

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery Protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard postoperative care (Control)
Number of subjects: 0
Study: 34569467

Group type: EXPERIMENTAL
Intervention: WeChat-based telemedicine intervention
Number of subjects: 1424

Group type: COMPARATOR
Intervention: Conventional community hospital follow-up
Number of subjects: 1424
Study: 34569839

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34569847

Group type: EXPERIMENTAL
Intervention: Evidence-based pediatric weight management intervention (PWMI); details on dosage and duration not available.
Number of subjects: 0
Study: 34569848

Group type: EXPERIMENTAL
Intervention: Pediatric weight management intervention, details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 34570085

Group type: EXPERIMENTAL
Intervention: Survey on attitudes and perceptions regarding pharmacogenomics
Number of subjects: 149
Study: 34570185

Group type: EXPERIMENTAL
Intervention: Hyperthyroid state
Number of subjects: 18

Group type: COMPARATOR
Intervention: Euthyroid state
Number of subjects: 18

Group type: COMPARATOR
Intervention: 3 months after normal thyroid function
Number of subjects: 18
Study: 34570342

Group type: EXPERIMENTAL
Intervention: Iodine deficiency
Number of subjects: 726
Study: 34570352

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No cardiopulmonary bypass (CPB)
Number of subjects: 35
Study: 34570534

Group type: EXPERIMENTAL
Intervention: Mindfulness training (not specified dosage or duration)
Number of subjects: 0
Study: 34570645

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 10
Study: 34570655

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R regimen (dose-adjusted etoposide, doxorubicin, cyclophosphamide with vincristine and prednisone plus rituximab)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Historical control (not specified in detail)
Number of subjects: 46
Study: 34570677

Group type: EXPERIMENTAL
Intervention: System Support Mapping (MAP)
Number of subjects: 24
Study: 34570768

Group type: EXPERIMENTAL
Intervention: Coronary endothelial-dependent variables (change in coronary blood flow and coronary diameter in response to cold pressor testing)
Number of subjects: 152
Study: 34570811

Group type: EXPERIMENTAL
Intervention: Computerized history-taking (CHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electronic health records (EHR)
Number of subjects: 0
Study: 34570984

Group type: EXPERIMENTAL
Intervention: Slow weight loss program
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fast weight loss program
Number of subjects: 30
Study: 34571258

Group type: EXPERIMENTAL
Intervention: Osteopathy (osteoporosis or osteopenia) identified via DXA scan
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Traumatic fractures
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Spontaneous fractures
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Underweight body mass index category
Number of subjects: 282
Study: 34571503

Group type: EXPERIMENTAL
Intervention: Portable, self-contained neuroprosthetic hand with deep learning-based finger control
Number of subjects: 0
Study: 34572728

Group type: EXPERIMENTAL
Intervention: Deep-Learning automatic segmentation algorithm (DLASA) for measuring muscle depletion (MD)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Deep-Learning automatic segmentation algorithm (DLASA)
Number of subjects: 656
Study: 34572852

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy followed by potentially curative gastric cancer resection
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Other events (concurrent distant metastasis, locoregional recurrence or death)
Number of subjects: 606
Study: 34573883

Group type: EXPERIMENTAL
Intervention: OCTA measurements in DM-no DR patients with HbA1c levels >7.5%
Number of subjects: 478
Study: 34574679

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Blueberry juice
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (cherry/blueberry flavoured)
Number of subjects: 45
Study: 34575192

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0
Study: 34575252

Group type: EXPERIMENTAL
Intervention: P-HNL Dimer
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: B-HNL
Number of subjects: 103
Study: 34576834

Group type: EXPERIMENTAL
Intervention: 2'fucosyllactose (2'FL) and lacto-N-neotetraose (LNnT) formula feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34579117

Group type: EXPERIMENTAL
Intervention: Full Healthy Primary School of the Future (HPSF)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Partial Healthy Primary School of the Future (HPSF)
Number of subjects: 833
Study: 34579646

Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion (CP); median infusion titers 1:320 U/mL (Interquartile range 1:80-1:320)
Number of subjects: 50
Study: 34579718

Group type: EXPERIMENTAL
Intervention: Severe multimorbidity (591; 6.5%)
Number of subjects: 9566

Group type: EXPERIMENTAL
Intervention: Moderate multimorbidity (4301; 47.6%)
Number of subjects: 9566

Group type: EXPERIMENTAL
Intervention: Mild multimorbidity (4147; 45.9%)
Number of subjects: 9566

Group type: COMPARATOR
Intervention: Severe multimorbidity compared to mild
Number of subjects: 9566

Group type: COMPARATOR
Intervention: Moderate multimorbidity compared to mild
Number of subjects: 9566

Group type: COMPARATOR
Intervention: Severe class compared to mild class
Number of subjects: 9566
Study: 34579767

Group type: EXPERIMENTAL
Intervention: WJ-MSC and rEMS combination (Group 1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Only rEMS (Group 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Only WJ-MSC (Group 3)
Number of subjects: 18
Study: 34579768

Group type: EXPERIMENTAL
Intervention: Modified natural cycle FET (corpus luteum present)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Programmed FET (corpus luteum absent)
Number of subjects: 788
Study: 34579775

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (target dose 97/103 mg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34579786

Group type: EXPERIMENTAL
Intervention: Immediate bivalent HPV vaccine and delayed meningococcal vaccine (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate nonavalent HPV vaccine and delayed meningococcal vaccine (group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate meningococcal vaccine and delayed HPV vaccine (group 3)
Number of subjects: 0
Study: 34580030

Group type: EXPERIMENTAL
Intervention: Transactional sex
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Transgender identity
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Recent unstable housing
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Perceived financial well-being
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Coerced sex
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Unstable housing and sexual coercion
Number of subjects: 454
Study: 34580115

Group type: EXPERIMENTAL
Intervention: HPV sequencing (HPV-seq)
Number of subjects: 0

Group type: COMPARATOR
Intervention: dPCR
Number of subjects: 0
Study: 34580336

Group type: EXPERIMENTAL
Intervention: Durvalumab and Paclitaxel combination therapy
Number of subjects: 14
Study: 34580404

Group type: EXPERIMENTAL
Intervention: TENS-R (right-sided shoulder TENS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TENS-L (left-sided shoulder TENS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TENS (control group)
Number of subjects: 0
Study: 34580668

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-positive patients with cancer
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Patients with hematological malignancies
Number of subjects: 357
Study: 34580673

Group type: EXPERIMENTAL
Intervention: 1 µg NDV-HXP-S vaccine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 3 µg NDV-HXP-S vaccine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 10 µg NDV-HXP-S vaccine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 3 µg+CpG1018 NDV-HXP-S vaccine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 1 µg+CpG1018 NDV-HXP-S vaccine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 34581443

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34581517

Group type: EXPERIMENTAL
Intervention: SBI-101 (ex vivo mesenchymal stem cells)
Number of subjects: 0
Study: 34581550

Group type: EXPERIMENTAL
Intervention: Ideal cardiovascular health for three or more of the seven health metrics
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Ideal cardiovascular health for two or fewer of the seven health metrics
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Poor cardiovascular health for three or more of the seven health metrics
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Poor cardiovascular health for two or fewer of the seven health metrics
Number of subjects: 474
Study: 34581712

Group type: EXPERIMENTAL
Intervention: Cognitive functioning (3MS)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Cognitive functioning (3MS) with METER
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Cognitive functioning (3MS) with REALM
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Health literacy (METER)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Health literacy (REALM)
Number of subjects: 298
Study: 34581757

Group type: EXPERIMENTAL
Intervention: RO6870810 + venetoclax
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RO6870810 + venetoclax + rituximab
Number of subjects: 39
Study: 34581764

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg twice daily (DL1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg twice daily (DL2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (both DLs)
Number of subjects: 18
Study: 34581770

Group type: EXPERIMENTAL
Intervention: 44-channel suprachoroidal retinal prosthesis
Number of subjects: 4
Study: 34581778

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 10
Study: 34581993

Group type: EXPERIMENTAL
Intervention: LLD concurrent with adolescent idiopathic scoliosis (AIS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: LLD without concurrent AIS
Number of subjects: 47
Study: 34582035

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Vitamin K Antagonist (VKA)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Direct Oral Anticoagulants (DOAC)
Number of subjects: 1042
Study: 34582080

Group type: EXPERIMENTAL
Intervention: Specialized guidewires, microcatheters, and guide catheter extensions for CTO revascularization
Number of subjects: 150
Study: 34582307

Group type: EXPERIMENTAL
Intervention: Model 1 (BMI, stress level, diastolic blood pressure, narcotic use in 1st trimester, uterine artery pulsatility index at 16-21 weeks)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Model 2 (Model 1 variables plus preterm delivery, preeclampsia, and suspected fetal growth restriction)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Composite perinatal morbidity
Number of subjects: 865
Study: 34582355

Group type: EXPERIMENTAL
Intervention: STAC-T web app prototype
Number of subjects: 16
Study: 34582354

Group type: EXPERIMENTAL
Intervention: CHAMPS Study and Registry
Number of subjects: 2762

Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires
Number of subjects: 2762

Group type: EXPERIMENTAL
Intervention: Longitudinal cohort
Number of subjects: 2762
Study: 34582377

Group type: EXPERIMENTAL
Intervention: Prime-boost vaccination regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prime-only vaccination regimen
Number of subjects: 0
Study: 34582562

Group type: COMPARATOR
Intervention: Antioxidants (silymarin)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Antipsychotics (olanzapine)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Cell signal transducers (inositol)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Glutamate modulators (N-acetylcysteine)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Opioid antagonists (naltrexone)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs; fluoxetine)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (clomipramine)
Number of subjects: 345
Study: 34582633

Group type: EXPERIMENTAL
Intervention: Standing Time (ST)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sedentary Behavior (SB)
Number of subjects: 72
Study: 34582724

Group type: EXPERIMENTAL
Intervention: Whole-body cooling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 34583638

Group type: EXPERIMENTAL
Intervention: Colonoscopy referral
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Pre-procedure visit completion
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Colonoscopy completion
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Time to colonoscopy
Number of subjects: 711
Study: 34583690

Group type: EXPERIMENTAL
Intervention: PAC-19QoL instrument
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group of unaffected participants
Number of subjects: 15
Study: 34583746

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon angioplasty
Number of subjects: 478

Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon angioplasty
Number of subjects: 478
Study: 34583762

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (1-ml triamcinolone 40 mg/1 ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Corticosteroid injection co-administered with 1-ml of 1% lidocaine
Number of subjects: 100
Study: 34584462

Group type: EXPERIMENTAL
Intervention: TVUS guided ET
Number of subjects: 800

Group type: COMPARATOR
Intervention: TAUS guided ET
Number of subjects: 800
Study: 34584574

Group type: EXPERIMENTAL
Intervention: Mobile mindful eating intervention
Number of subjects: 0
Study: 34585083

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 1567

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 1567
Study: 34585271

Group type: EXPERIMENTAL
Intervention: Direct ICU admission
Number of subjects: 530

Group type: COMPARATOR
Intervention: Delayed ICU admission
Number of subjects: 530
Study: 34585329

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Reference group (Control)
Number of subjects: 79
Study: 34585343

Group type: EXPERIMENTAL
Intervention: Non-invasive central pressure estimation before endovascular repair
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-invasive central pressure estimation after endovascular repair
Number of subjects: 20
Study: 34585621

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 296

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 296
Study: 34585638

Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy for endometrioma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other types of infertility (unexplained, tubal factor, male factor)
Number of subjects: 0
Study: 34585740

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with antimalarial drugs
Number of subjects: 13
Study: 34585950

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 301
Study: 34586075

Group type: EXPERIMENTAL
Intervention: POD Adventures intervention delivered over 4 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care comprising information about local mental health services and national helplines
Number of subjects: 70
Study: 34586417

Group type: EXPERIMENTAL
Intervention: Continuous kidney replacement therapy (CKRT)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Children with three comorbidities
Number of subjects: 340

Group type: COMPARATOR
Intervention: Children with no comorbidities
Number of subjects: 340
Study: 34586461

Group type: EXPERIMENTAL
Intervention: Diaphragmatic traction suture
Number of subjects: 43

Group type: COMPARATOR
Intervention: No intervention (control group not explicitly mentioned)
Number of subjects: 43
Study: 34586478

Group type: EXPERIMENTAL
Intervention: Crizotinib (100-215 mg/m, orally once or twice-daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Crizotinib in combination with dasatinib
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Crizotinib in overweight/obese patients
Number of subjects: 36
Study: 34586748

Group type: EXPERIMENTAL
Intervention: molar NT-proBNP/BNP ratio
Number of subjects: 782

Group type: COMPARATOR
Intervention: NT-proBNP or BNP alone
Number of subjects: 782
Study: 34586924

Group type: EXPERIMENTAL
Intervention: Hypoxic gene expression classifier
Number of subjects: 190

Group type: COMPARATOR
Intervention: Chemo-radiation and image guided adaptive brachytherapy
Number of subjects: 190
Study: 34587198

Group type: EXPERIMENTAL
Intervention: Telehealth intervention including remote monitoring through ABPM, ECG, spirometry, sleep oximetry, and a smartphone app for home monitoring of BP, HR, SpO2, body temperature, body weight, waist circumference, blood glucose, and lipids.
Number of subjects: 13613

Group type: EXPERIMENTAL
Intervention: Telehealth intervention during lockdown period.
Number of subjects: 13613

Group type: EXPERIMENTAL
Intervention: Post-lockdown period monitoring.
Number of subjects: 13613
Study: 34587245

Group type: EXPERIMENTAL
Intervention: High nutritional risk (NutriSTEP score ≥21)
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: 1-SD increase in NutriSTEP total score
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: NutriSTEP total score
Number of subjects: 896
Study: 34587246

Group type: EXPERIMENTAL
Intervention: FlowCT analysis of T-cell compartment in bone marrow (BM) and peripheral blood (PB)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: FlowCT analysis of T-cell compartment in BM of patients with active MM after treatment intensification
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 250
Study: 34587796

Group type: EXPERIMENTAL
Intervention: 3D-MERGE MRI
Number of subjects: 227

Group type: COMPARATOR
Intervention: 2D-MC MRI
Number of subjects: 227
Study: 34587913

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for AIS in patients with AF
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Endovascular treatment (EVT) for AIS in patients without AF
Number of subjects: 1755
Study: 34588193

Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab (8 mg·kg)
Number of subjects: 29
Study: 34588255

Group type: EXPERIMENTAL
Intervention: First pulmonary embolism with cardiac involvement
Number of subjects: 417

Group type: COMPARATOR
Intervention: First pulmonary embolism without cardiac involvement (non-severe)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Provoked PE with cardiac involvement
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Severity of first PE
Number of subjects: 417
Study: 34588264

Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI) assessment of decision-making capacity (DMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical assessment of DMC by a geriatrician based on neuropsychological tests
Number of subjects: 0